Hox Therapeutics Ltd, a UK-based private biotechnology company developing highly targeted cancer therapies, announced on Tuesday that it has collaborated with Vernalis (R&D) Ltd, a UK-based fully owned subsidiary of China-based HitGen Inc.
The collaboration is aimed at identifying inhibitors against an undisclosed oncology target.
According to the terms of the contract, Vernalis is to utilise its protein science and Hit ID platforms to produce the target protein, and to identify and characterise small molecule inhibitors of the target. Hox is to fund the research at Vernalis.
Financial terms of the agreement were not revealed.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member